Rallybio Q2 net loss $9.7M, sells REV102 to Recursion for $25M; RLYB116 data Q3/Q4 2025

Rallybio Corp

2025-Q2 EPS reported -$0.43 revenue$424,000

Net loss of $9.7M ($0.22/share) vs $16.2M in Q2 2024; revenue $0.2M.
Sold REV102 to Recursion for up to $25M, including $7.5M upfront equity; cash runway extended into mid-2027.
RLYB116 confirmatory PK/PD study dosing started; Cohort 1 and Cohort 2 topline data expected Q3 and Q4 2025.
RLYB212 program discontinued after Phase 2 PK data missed target concentrations.
Cash, equivalents and marketable securities $45.7M at June 30, 2025; with REV102 payment, runway into mid-2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.